Business news – Page 105

  • Business

    Dow partners with Oz university

    2012-03-30T00:00:00Z

    Dow is to partner with the University of Queensland in Australia

  • Business

    Seroquel patent row continues

    2012-03-30T00:00:00Z

    The legal tug of war over the right to sell generic versions of Seroquel (quetiapine) tablets continues

  • Business

    Half of sun products have BASF UV filters

    2012-03-30T00:00:00Z

    German chemical giant BASF says that 50% of all ‘sun care’ products sold today contain its organic UV-A filters

  • Business

    US approves new anaemia drug

    2012-03-30T00:00:00Z

    US authorities have approved Omontys (peginesatide) injections for treating anaemia in dialysis patients with chronic kidney disease

  • Business

    Business roundup: April 2012

    2012-03-28T09:28:00Z

    Pharmaceutical A pill to keep you off the pints? Source: © IStockphoto Beer today, gone tomorrow - Selincro tablets might help patients put their alcohol problems behind them Phase III trials of Selincro (nalmefene) tablets show that it outperforms placebo treatment when used to help patients with ...

  • Business

    Light materials from Bayer

    2012-03-28T00:00:00Z

    Bayer has launched a lightweight material designed to replace steel in railway locomotive and carriage construction

  • Business

    PCSK9 inhibitors against cholesterol problems perform well

    2012-03-28T00:00:00Z

    Sanofi has reported Phase II data for a new drug candidate for lowering cholesterol levels in patients already taking statins

  • Business

    $500m for Ista

    2012-03-28T00:00:00Z

    US eye drug company Bausch & Lomb has signed a cash deal to buy US drugmaker Ista Pharmaceuticals for $9.10 per share, equivalent to $500 million

  • Business

    Court throws out patent covering drug dosing

    2012-03-23T00:00:00Z

    The US Supreme Court has said that medical tests that rely on correlations between drug doses and treatment cannot be patented

  • Business

    EPA proposes new rules for five chemicals

    2012-03-23T00:00:00Z

    The US Environmental Protection Agency has proposed new rules that would force companies to report any new use

  • Business

    AbbVie emerges from Abbott split

    2012-03-23T00:00:00Z

    US healthcare giant Abbott has renamed the branded drugs part of its business

  • Business

    GSK to build £350m factory in UK

    2012-03-22T00:00:00Z

    GlaxoSmithKline (GSK) has announced £350 million plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria

  • News

    GSK to build £350 million factory in UK

    2012-03-22T00:00:00Z

    Tax breaks in the UK budget have prompted GSK to reaffirm its commitment

  • News

    India green lights production of patented cancer drug

    2012-03-20T00:00:00Z

    For the first time India has invoked a ‘compulsory licence’ clause to cut the cost of a patented anti-cancer drug

  • FEATURE_SITE-PROFILES_pg060_250
    Feature

    Rising from the ashes

    2012-02-24T09:08:00Z

    Neil Sinclair reports on some exciting new ventures emerging from redundant chemical and pharmaceutical plants

  • IN-THE-PIPELINE_250
    Opinion

    The elements of drug design

    2012-02-23T13:01:00Z

    Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love

  • Business

    Business roundup: March 2012

    2012-02-23T11:24:00Z

    Pharmaceutical Collaboration for neglected tropical diseases A group of 13 pharma companies, three national governments and several global health organisations has come together to target 10 neglected tropical diseases (NTDs) with $785 million (?497 million) in R&D funding. The group aims to ’accelerate progress toward eliminating or controlling [this set ...

  • Opinion

    The language of the lab

    2012-01-27T10:21:00Z

    Derek Lowe wonders what the lab lingua franca might be in the years to come

  • Business

    Business roundup: February 2012

    2012-01-27T09:27:00Z

    Pharmaceutical BMS spends $2.5 billion on antiviral firm Pharma giant Bristol-Myers Squibb (BMS) has struck a deal to buy US biotech Inhibitex for $2.5 billion (?1.6 billion). The move will stock BMS’s pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating ...

  • Opinion

    Rewards of repurposing

    2011-12-22T10:14:00Z

    Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about